Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
Purpose
This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to other places in the body (advanced). The second part of this study will also help to find out if the cisplatin given weekly approach will extend patients' life by at least the same amount of time as the cisplatin given every three weeks approach. Cisplatin is in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Radiation with low-dose cisplatin given weekly may be effective in shrinking or stabilizing head and neck cancer or preventing its recurrence.
Conditions
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Hypopharyngeal Squamous Cell Carcinoma
- Advanced Laryngeal Squamous Cell Carcinoma
- Advanced Oropharyngeal Squamous Cell Carcinoma
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Pathologically (histologically or cytologically) proven diagnosis of SCCHN of the oropharynx, larynx, hypopharynx, or p16-positive unknown primary prior to registration; specimen from cervical lymph nodes with a well-defined primary site documented clinically or radiologically is acceptable; in patients with carcinoma of unknown primary this will be sufficient for pathologic confirmation without a clinically or radiographically defined primary site - For patients with oropharyngeal cancer (OPC)/cancer of unknown primary (CUP): P16 status based on local site immunohistochemical tissue staining is required. A cell block obtained from a fine needle aspiration (FNA) biopsy specimen may be used as the sole diagnostic tissue. Centers are encouraged to contact the pathology chair for clarification. - Note: Institutions must screen patients for p16 status by immunohistochemistry (IHC) in order to be eligible for the trial using a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. A rigorous laboratory accreditation process similar to the United States (U.S.) CLIA certification, such as the provincial accreditation status offered by the Ontario Laboratory Accreditation (OLA) Program in Canada, the College of American Pathologists (CAP), or an equivalent accreditation in other countries, is acceptable. - The p16 results must be reported on the pathology report being submitted. The p16 positivity is defined as > 70% of tumor cells showing strong nuclear and/or cytoplasmic immunostaining with p16 antibody. - For patients with laryngeal and hypopharyngeal primaries: Analysis of p16 status is NOT required. - Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. Simple tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving =< 4 nodes are permitted and considered as non-therapeutic nodal excisions - Clinical stage (American Joint Committee on Cancer [AJCC], 8th ed.), including no distant metastases based on the following diagnostic workup: - History/physical examination within 60 days prior to registration - One of the following imaging studies is required within 60 days prior to registration: - Computed tomography (CT) scan of neck (diagnostic quality with contrast, unless contraindicated) OR - Magnetic resonance imaging (MRI) of the neck (diagnostic quality with contrast, unless contraindicated) OR - Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT of the neck; the CT component must be of diagnostic quality with contrast, unless contraindicated. - Note: A diagnostic quality CT or MRI with contrast or FDG-PET/CT scan of neck performed for the purposes of radiation planning may serve as both staging and planning tools - One of the following imaging studies is required within 60 days prior to registration: - FDG-PET/CT of the chest; FDG-PET/CT scan is strongly preferred and highly recommended to be used for eligibility OR - Chest CT - Exam with laryngopharyngoscopy (mirror or in office direct procedure acceptable) within 70 days prior to registration; - Eligibility by patient cohort; - Non-OPC/p16-negative OPC Cohort; Tumor Site: Larynx/Hypopharynx; Clinical Staging (AJCC, 8th ed.): T3-4 N0 or T1-4 N1-3 T2 N0 (hypopharynx only) - Tumor Site: p16-negative OPC; Clinical Staging (AJCC, 8th ed.): T2N1, T1-4 N2-3, or T3-4 N0-1 - p16-positive OPC/CUP Cohort; - Tumor Site: OPC; Smoking Status: =< 10 pack-years; Clinical Staging (AJCC, 8th ed.): T1-3 N2-3 or T4 N0-3 - Tumor Site: OPC; Smoking Status: > 10 pack-years; Clinical Staging (AJCC, 8th ed.): T1N2-3, T2N1-3, or T3-4 N0-3 - Tumor Site: CUP; Smoking Status: Any; Clinical Staging (AJCC, 8th ed.): T0 N2-3 Note: Cigar and pipe tobacco consumption is not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is also no clear scientific evidence regarding the role of chewing tobacco-containing products in oropharyngeal cancer, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators should not count use of non-cigarette tobacco products in the pack-years calculation. - Age >= 18 - Zubrod (Eastern Cooperative Oncology Group [ECOG]) performance status of 0-1 within 14 days prior to registration - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 30 days prior to registration) - Platelets >= 75,000 cells/mm^3 (within 30 days prior to registration) - Hemoglobin >= 8.0 g/dL (within 30 days prior to registration) - Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dL is acceptable) - Calculated creatinine clearance (CrCl) >= 50 mL/min by the Cockcroft-Gault formula (within 30 days prior to registration) - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 30 days prior to registration) (not applicable to patients with known Gilbert's syndrome) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x institutional ULN (within 30 days prior to registration) - Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and CD4 T Cell count > 200 cells/mm^3 are eligible for this trial. Testing is not required for entry into protocol - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes - Willing to use highly effective contraceptives for participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) during therapy and for 14 months (females); for 11 months (males) following last dose of cisplatin; this inclusion is necessary because the treatment in this study may be significantly teratogenic. - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria
- Patients with oral cavity cancer, nasopharynx cancer, or p16-negative cancer of unknown primary (CUP) - Recurrence of the study cancer - Definitive clinical or radiologic evidence of distant metastatic disease - Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, any prior exposure to cisplatin is excluded - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Severe, active co-morbidity defined as follows: - Unstable angina requiring hospitalization in the last 6 months - Myocardial infarction within the last 6 months - New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.) - Persistent grade 3-4 (CTCAE version 5.0) electrolyte abnormalities that cannot be reversed despite replacement as indicated by repeat testing - Patient must not have an active infection requiring IV antibiotics prior to registration; - Other chronic renal disease like nephrotic syndrome, that could be worsened by cisplatin therapy - History of allogenic organ transplantation - Any symptomatic peripheral sensory neuropathy grade >= 2 (CTCAE version 5.0); - Pregnancy and individuals unwilling to discontinue nursing - History of hypersensitivity to cisplatin or platinum-containing compounds
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator ARM I (radiation therapy, every 3 week cisplatin) |
Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive cisplatin IV once Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, or MRI or PET scan throughout the study. |
|
Experimental Arm II (radiation therapy, weekly cisplatin) |
Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive weekly cisplatin IV QW for 7 weeks during radiation therapy in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, or MRI or PET scan throughout the study. |
|
Recruiting Locations
Mobile 4076598, Alabama 4829764 36607
Site Public Contact
251-435-3942
Jonesboro 4116834, Arkansas 4099753 72401
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Anaheim 5323810, California 5332921 92806
Antioch 5324200, California 5332921 94531
Auburn 5325223, California 5332921 95602
Auburn 5325223, California 5332921 95603
Bellflower 5327422, California 5332921 90706
Berkeley 5327684, California 5332921 94704
Beverly Hills 5328041, California 5332921 90211
Carmichael 5334336, California 5332921 95608
Carmichael 5334336, California 5332921 95608
Costa Mesa 5339840, California 5332921 92627
Site Public Contact
877-827-8839
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Elk Grove 5346111, California 5332921 95758
Encinitas 5346646, California 5332921 92024
Site Public Contact
760-536-7700
Fremont 5350734, California 5332921 94538
Fremont 5350734, California 5332921 94538
Fresno 5350937, California 5332921 93720
Fresno 5350937, California 5332921 93720
Irvine 5359777, California 5332921 92612
Irvine 5359777, California 5332921 92618
La Jolla 5363943, California 5332921 92093
Los Angeles 5368361, California 5332921 90025
Los Angeles 5368361, California 5332921 90027
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Marysville 5370984, California 5332921 95901
Site Public Contact
530-749-4400
Modesto 5373900, California 5332921 95355
Modesto 5373900, California 5332921 95356
Mountain View 5375480, California 5332921 94040
Oakland 5378538, California 5332921 94611
Oakland 5378538, California 5332921 94611
Ontario 5379439, California 5332921 91761
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94301
Palo Alto 5380748, California 5332921 94304
Palo Alto 5380748, California 5332921 94304
Site Public Contact
800-455-0057
Rancho Cordova 5385941, California 5332921 95670
Redwood City 5386834, California 5332921 94063
Site Public Contact
877-642-4691
Richmond 5387428, California 5332921 94801
Rocklin 5388319, California 5332921 95765
Rohnert Park 5388564, California 5332921 94928
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95678
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
Sacramento 5389489, California 5332921 95823
Sacramento 5389489, California 5332921 95823
San Diego 5391811, California 5332921 92103
San Francisco 5391959, California 5332921 94115
San Francisco 5391959, California 5332921 94115
Site Public Contact
877-827-3222
San Francisco 5391959, California 5332921 94158
San Jose 5392171, California 5332921 95119
San Jose 5392171, California 5332921 95124
San Leandro 5392263, California 5332921 94577
San Rafael 5392567, California 5332921 94903
Santa Clara 5393015, California 5332921 95051
Santa Rosa 5393287, California 5332921 95403
Santa Rosa 5393287, California 5332921 95403
South San Francisco 5397765, California 5332921 94080
South San Francisco 5397765, California 5332921 94080
Stockton 5399020, California 5332921 95210
Sunnyvale 5400075, California 5332921 94086
Truckee 5403676, California 5332921 96161
Site Public Contact
530-582-6450
Vacaville 5405228, California 5332921 95688
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Woodland 5410430, California 5332921 95695
Colorado Springs 5417598, Colorado 5417618 80923
Denver 5419384, Colorado 5417618 80205
Denver 5419384, Colorado 5417618 80218
Site Public Contact
303-318-3413
Golden 5423294, Colorado 5417618 80401
Lafayette 5427771, Colorado 5417618 80026
Lone Tree 5429208, Colorado 5417618 80124
Washington D.C. 4140963, District of Columbia 4138106 20007
Site Public Contact
202-444-2223
Washington D.C. 4140963, District of Columbia 4138106 20037
Site Public Contact
202-741-2210
Aventura 4146429, Florida 4155751 33180
Site Public Contact
954-461-2180
Bay Pines 4146855, Florida 4155751 33744
Coral Gables 4151871, Florida 4155751 33146
Site Public Contact
305-243-2647
Deerfield Beach 4153071, Florida 4155751 33442
Site Public Contact
305-243-2647
Miami 4164138, Florida 4155751 33136
Site Public Contact
305-243-2647
Miami 4164138, Florida 4155751 33176
Site Public Contact
305-243-2647
Plantation 4168782, Florida 4155751 33324
Site Public Contact
305-243-2647
Tampa 4174757, Florida 4155751 33607
Tampa 4174757, Florida 4155751 33612
Tampa 4174757, Florida 4155751 33612
Wesley Chapel 4177727, Florida 4155751 33544
Augusta 4180531, Georgia 4197000 30912
Aurora 4883817, Illinois 4896861 60504
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Centralia 4235587, Illinois 4896861 62801
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-864-5204
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
Effingham 4237727, Illinois 4896861 62401
Effingham 4237727, Illinois 4896861 62401
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Hines 4896005, Illinois 4896861 60141
Site Public Contact
708-202-8387
Kewanee 4898433, Illinois 4896861 61443
Macomb 4900817, Illinois 4896861 61455
Mattoon 4244099, Illinois 4896861 61938
Maywood 4901514, Illinois 4896861 60153
Site Public Contact
708-226-4357
O'Fallon 4245926, Illinois 4896861 62269
O'Fallon 4245926, Illinois 4896861 62269
Ottawa 4905006, Illinois 4896861 61350
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61636
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Rockford 4907959, Illinois 4896861 61114
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Urbana 4914570, Illinois 4896861 61801
Washington 4915545, Illinois 4896861 61571
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Clive 4852065, Iowa 4862182 50325
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Creston 4853078, Iowa 4862182 50801
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-282-2200
Des Moines 4853828, Iowa 4862182 50314
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50316
Site Public Contact
515-241-8704
Waukee 4880981, Iowa 4862182 50263
Site Public Contact
515-241-3305
West Des Moines 4881346, Iowa 4862182 50266-7700
Site Public Contact
515-343-1000
West Des Moines 4881346, Iowa 4862182 50266
Kansas City 4273837, Kansas 4273857 66160
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Westwood 4281639, Kansas 4273857 66205
Lexington 4297983, Kentucky 6254925 40504
Lexington 4297983, Kentucky 6254925 40504
Lexington 4297983, Kentucky 6254925 40509
Lexington 4297983, Kentucky 6254925 40536
Site Public Contact
859-257-3379
Louisville 4299276, Kentucky 6254925 40202
Site Public Contact
502-562-3429
Louisville 4299276, Kentucky 6254925 40245
New Orleans 4335045, Louisiana 4331987 70112
New Orleans 4335045, Louisiana 4331987 70112
Bath 4957570, Maine 4971068 04530
Biddeford 4958141, Maine 4971068 04005
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
Portland 4975802, Maine 4971068 04102
Sanford 4977762, Maine 4971068 04073
Sanford 4977762, Maine 4971068 04073
Site Public Contact
207-459-1600
Scarborough 4977882, Maine 4971068 04074
South Portland 4979244, Maine 4971068 04106
Baltimore 4347778, Maryland 4361885 21201
Baltimore 4347778, Maryland 4361885 21201
Site Public Contact
800-888-8823
Bel Air 4348240, Maryland 4361885 21014
Site Public Contact
443-643-3010
Columbia 4352053, Maryland 4361885 21044
Site Public Contact
443-546-1300
Glen Burnie 4356188, Maryland 4361885 21061
Site Public Contact
410-553-8100
Ann Arbor 4984247, Michigan 5001836 48106
Ann Arbor 4984247, Michigan 5001836 48109
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48116
Site Public Contact
800-865-1125
Brownstown, Michigan 5001836 48183
Canton 4987990, Michigan 5001836 48188
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Chelsea 4988628, Michigan 5001836 48118
Clinton Township 4989133, Michigan 5001836 48038
Dearborn 4990510, Michigan 5001836 48126
Detroit 4990729, Michigan 5001836 48202
Detroit 4990729, Michigan 5001836 48236
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Jackson 4997384, Michigan 5001836 49201
Livonia 4999837, Michigan 5001836 48154
Novi 5004062, Michigan 5001836 48374
Novi 5004062, Michigan 5001836 48377
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Southfield 5010636, Michigan 5001836 48075
Warren 5014051, Michigan 5001836 48093
West Bloomfield 7259621, Michigan 5001836 48322
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Saint Cloud 5044407, Minnesota 5037779 56303
Columbus 4422442, Mississippi 4436296 39705
Grenada 4428539, Mississippi 4436296 38901
Gulfport 4428667, Mississippi 4436296 39502
Jackson 4431410, Mississippi 4436296 39216
Site Public Contact
601-815-6700
New Albany 4438121, Mississippi 4436296 38652
Oxford 4440076, Mississippi 4436296 38655
Southhaven 4446702, Mississippi 4436296 38671
Cape Girardeau 4379966, Missouri 4398678 63703
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Joplin 4392768, Missouri 4398678 64804
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
North Kansas City 4400860, Missouri 4398678 64116
Rolla 4406282, Missouri 4398678 65401
Site Public Contact
573-458-6379
Rolla 4406282, Missouri 4398678 65401
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
Springfield 4409896, Missouri 4398678 65807
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Bozeman 5641727, Montana 5667009 59715
Butte 5642934, Montana 5667009 59701
Site Public Contact
406-723-2621
Great Falls 5655240, Montana 5667009 59405
Havre 5656497, Montana 5667009 59501
Bellevue 5063805, Nebraska 5073708 68123
Omaha 5074472, Nebraska 5073708 68118
Site Public Contact
402-559-5600
Omaha 5074472, Nebraska 5073708 68198
Lebanon 5088597, New Hampshire 5090174 03756
Albuquerque 5454711, New Mexico 5481136 87106
Buffalo 5110629, New York 5128638 14263
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
Rochester 5134086, New York 5128638 14620
Site Public Contact
585-341-8113
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
Webster 5143495, New York 5128638 14580
Pinehurst 4485272, North Carolina 4482348 28374
Supply 4830472, North Carolina 4482348 28462
Site Public Contact
910-754-4716
Wilkesboro 4499138, North Carolina 4482348 28659
Site Public Contact
888-716-9253
Wilmington 4499379, North Carolina 4482348 28401
Site Public Contact
910-251-1839
Wilmington 4499379, North Carolina 4482348 28401
Site Public Contact
910-342-3000
Winston-Salem 4499612, North Carolina 4482348 27157
Site Public Contact
336-713-6771
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Akron 5145476, Ohio 5165418 44304
Avon 5146277, Ohio 5165418 44011
Site Public Contact
800-641-2422
Barberton 5146491, Ohio 5165418 44203
Beavercreek 4506008, Ohio 5165418 45431
Centerville 4508204, Ohio 5165418 45459
Centerville 4508204, Ohio 5165418 45459
Cleveland 5150529, Ohio 5165418 44106
Cleveland 5150529, Ohio 5165418 44109
Cleveland 5150529, Ohio 5165418 44111
Cleveland 5150529, Ohio 5165418 44195
Columbus 4509177, Ohio 5165418 43210
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45415
Dayton 4509884, Ohio 5165418 45415
Franklin 4512203, Ohio 5165418 45005-1066
Franklin 4512203, Ohio 5165418 45005
Greenville 5156493, Ohio 5165418 45331
Site Public Contact
937-569-7515
Kettering 4515843, Ohio 5165418 45429
Mansfield 5161723, Ohio 5165418 44906
Mayfield Heights 5162188, Ohio 5165418 44124
Medina 5162512, Ohio 5165418 44256
Mentor 5162645, Ohio 5165418 44060
Ravenna 5167737, Ohio 5165418 44266
Sandusky 5170691, Ohio 5165418 44870
Strongsville 5173237, Ohio 5165418 44136
Sylvania 5173572, Ohio 5165418 43560
Toledo 5174035, Ohio 5165418 43606
Troy 5174358, Ohio 5165418 45373
Wooster 5177358, Ohio 5165418 44691
Oklahoma City 4544349, Oklahoma 4544379 73104
Bryn Mawr 5182063, Pennsylvania 6254927 19010
Erie 5188843, Pennsylvania 6254927 16544
Site Public Contact
814-452-5000
Hershey 5193342, Pennsylvania 6254927 17033-0850
Jefferson Hills 5195297, Pennsylvania 6254927 15025
Media 4559575, Pennsylvania 6254927 19063
Monroeville 5201734, Pennsylvania 6254927 15146
Site Public Contact
412-858-7746
Paoli 5205037, Pennsylvania 6254927 19301
Philadelphia 4560349, Pennsylvania 6254927 19111
Site Public Contact
215-728-4790
Philadelphia 4560349, Pennsylvania 6254927 19140
Site Public Contact
215-728-2983
Pittsburgh 5206379, Pennsylvania 6254927 15212
Site Public Contact
877-284-2000
Wexford 5219062, Pennsylvania 6254927 15090
Wynnewood 5220230, Pennsylvania 6254927 19096
Charleston 4574324, South Carolina 4597040 29425
Greenwood 4580569, South Carolina 4597040 29646
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Collierville 4614748, Tennessee 4662168 38017
Memphis 4641239, Tennessee 4662168 38120
Baytown 4672731, Texas 4736286 77521
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
Site Public Contact
713-873-2000
Houston 4699066, Texas 4736286 77030
Site Public Contact
713-790-2700
Houston 4699066, Texas 4736286 77070
Houston 4699066, Texas 4736286 77094
Site Public Contact
832-522-2873
Nassau Bay 4713813, Texas 4736286 77058
Sugar Land 4734825, Texas 4736286 77479
Site Public Contact
281-242-2873
The Woodlands 4736476, Texas 4736286 77385
American Fork 5844096, Utah 5549030 84003
Cedar City 5536630, Utah 5549030 84720
Logan 5777544, Utah 5549030 84321
Murray 5778755, Utah 5549030 84107
Ogden 5779206, Utah 5549030 84403
Provo 5780026, Utah 5549030 84604
Riverton 5780557, Utah 5549030 84065
Salt Lake City 5780993, Utah 5549030 84106
Salt Lake City 5780993, Utah 5549030 84112
Salt Lake City 5780993, Utah 5549030 84143
St. George 5546220, Utah 5549030 84770
Saint Johnsbury 5240656, Vermont 5242283 05819
Alexandria 4744091, Virginia 6254928 22304
Fairfax 4758023, Virginia 6254928 22031
Fairfax 4758023, Virginia 6254928 22033
Bellevue 5786882, Washington 5815135 98004
Site Public Contact
425-454-2148
Kirkland 5799841, Washington 5815135 98034
Site Public Contact
425-899-6000
Seattle 5809844, Washington 5815135 98109
Site Public Contact
800-804-8824
Seattle 5809844, Washington 5815135 98133
Site Public Contact
206-606-5800
Seattle 5809844, Washington 5815135 98195
Site Public Contact
800-804-8824
Charleston 4801859, West Virginia 4826850 25304
Site Public Contact
304-388-9944
Antigo 5244010, Wisconsin 5279468 54409
Eau Claire 5251436, Wisconsin 5279468 54701
Johnson Creek 5257996, Wisconsin 5279468 53038
La Crosse 5258957, Wisconsin 5279468 54601
Madison 5261457, Wisconsin 5279468 53705
Site Public Contact
608-256-1901
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marshfield 5261969, Wisconsin 5279468 54449
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Milwaukee 5263045, Wisconsin 5279468 53295
Site Public Contact
888-469-6614
Minocqua 5263156, Wisconsin 5279468 54548
Mukwonago 5263965, Wisconsin 5279468 53149
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Rhinelander 5268720, Wisconsin 5279468 54501
Rice Lake 5268798, Wisconsin 5279468 54868
Stevens Point 5274644, Wisconsin 5279468 54481
Stevens Point 5274644, Wisconsin 5279468 54482
Waukesha 5278052, Wisconsin 5279468 53188
Wausau 5278120, Wisconsin 5279468 54401
Site Public Contact
877-405-6866
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
Weston 5278693, Wisconsin 5279468 54476
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT05050162
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVES: I. To determine whether radiation with cisplatin weekly is superior in terms of acute toxicity, as measured by the T-scores (TAME method), to radiation with cisplatin every 3 weeks for patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). (Phase II) II. To determine whether radiation with cisplatin weekly is non-inferior to radiation with cisplatin every 3 weeks in terms of overall survival (OS) for patients with locoregionally advanced SCCHN. (Phase III) III. To determine whether radiation with cisplatin weekly is superior in terms of acute toxicity, as measured by the T-scores (TAME method), to radiation with cisplatin every 3 weeks for patients with locoregionally advanced SCCHN. (Phase III) SECONDARY OBJECTIVES: I. To assess and compare progression-free survival (PFS) between arms. II. To assess and compare locoregional failure and distant metastasis between arms. III. To assess acute and late toxicity (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0). IV. To assess patient-reported outcomes quality of life (PRO/QOL), as measured by the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) (primary PRO), between arms. V. To assess hearing loss, as measured by audiograms and the modified TUNE grading scale between arms. VI. To assess hearing loss, as measured by speech audiometry Consonant-Nucleus-Consonant word scores and tympanometry (subject to the modified TUNE grading scale testing results; otherwise, it will be an exploratory objective). VII. To assess hearing-related QOL as measured by the Hearing Handicap Inventory-Screening (HHIA-S) (secondary PRO), between arms. VIII. To assess long-term PFS, OS, and toxicity between arms. IX. To assess 3-year restricted-mean survival time for OS and PFS between arms (if long-term update is warranted). EXPLORATORY OBJECTIVE: I. To collect blood and tissue specimens for future translational science studies. For instance, to examine how germline and somatic genetic variants, such as TP53, CDKN2A, PIK3CA, PTEN, NFE2L2, and KEAP1, may influence cisplatin-related efficacy and toxicity, and to assess the effect of regular nonsteroidal anti-inflammatory drugs (NSAIDs) use and genomic activation of PIK3CA (mutation or amplification) or loss of PTEN, the negative regulator of PI3K, on disease-free survival or overall survival. OUTLINE: Patients are assigned to 1 of 2 arms. ARM I (NON-OROPHARYNGEAL CANCER [OPC]/p16-NEGATIVE OPC group and p16-NEGATIVE OPC/CANCER OF UNKNOWN PRIMARY [CUP] group): Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive cisplatin intravenously (IV) once every 3 weeks (Q3W) (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity. ARM II (NON-OROPHARYNGEAL CANCER [OPC]/p16-NEGATIVE OPC group and p16-NEGATIVE OPC/CANCER OF UNKNOWN PRIMARY [CUP] group): Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive cisplatin IV once a week (QW) for 7 weeks during radiation therapy in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan, or magnetic resonance imaging (MRI) or position emission tomography (PET) scan throughout the study.